# COVID19-流行病文献与数据整理

Created: November 29, 2022 8:32 PM

## 文献整理

### 
- 抗体免疫差异
    1. **Differential neutralization and inhibition of SARS-CoV-2 variants by antibodies elicited by COVID-19 mRNA vaccines：**[https://www.nature.com/articles/s41467-022-31929-6](https://www.nature.com/articles/s41467-022-31929-6)
    2. **Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4, & BA.5：**[https://www.nature.com/articles/s41586-022-05053-w](https://www.nature.com/articles/s41586-022-05053-w)
    3. **Neutralization of Omicron BA.1, BA.2, and BA.3 SARS-CoV-2 by 3 doses of BNT162b2 vaccine：**[https://www.nature.com/articles/s41467-022-30681-1](https://www.nature.com/articles/s41467-022-30681-1)
    4. **Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection：**[https://www.nature.com/articles/s41586-021-03696-9](https://www.nature.com/articles/s41586-021-03696-9)
    5. **Levels of SARS-CoV-2 antibodies among fully vaccinated individuals with Delta or Omicron variant breakthrough infections：**[https://www.nature.com/articles/s41467-022-32254-8](https://www.nature.com/articles/s41467-022-32254-8)
    6. **Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA.1 and BA.2 subvariants in Qatar：**[https://www.nature.com/articles/s41467-022-30895-3](https://www.nature.com/articles/s41467-022-30895-3)
    7. **Rapid evaluation of COVID-19 vaccine effectiveness against symptomatic infection with SARS-CoV-2 variants by analysis of genetic distance：**[https://www.nature.com/articles/s41591-022-01877-1](https://www.nature.com/articles/s41591-022-01877-1)
    8. **Population antibody responses following COVID-19 vaccination in 212,102 individuals:** [https://www.nature.com/articles/s41467-022-28527-x](https://www.nature.com/articles/s41467-022-28527-x)
    9. **The impact of pre-existing cross-reactive immunity on SARS-CoV-2 infection and vaccine responses：**[https://www.nature.com/articles/s41577-022-00809-x#Sec15](https://www.nature.com/articles/s41577-022-00809-x#Sec15)
- 接种犹豫/意愿
    1. **Revisiting COVID-19 vaccine hesitancy around the world using data from 23 countries in 2021:** [https://www.nature.com/articles/s41467-022-31441-x](https://www.nature.com/articles/s41467-022-31441-x)
    2. **Factors contributing to vaccine hesitancy and reduced vaccine confidence in rural underserved populations：**[https://www.nature.com/articles/s41599-022-01439-3](https://www.nature.com/articles/s41599-022-01439-3)
    3. **Vaccination rates are falling, and it’s not just the COVID-19 vaccine that people are refusing：**[https://www.nature.com/articles/d41586-022-04341-9](https://www.nature.com/articles/d41586-022-04341-9)
- 疫苗有效性和持续性
    1. **Effectiveness and protection duration of Covid-19 vaccines and previous infection against any SARS-CoV-2 infection in young adults：**[https://www.nature.com/articles/s41467-022-31469-z](https://www.nature.com/articles/s41467-022-31469-z)
    2. **Six months SARS-CoV-2 serology in a cohort of mRNA vaccinated subjects over 90 years old：**[https://www.nature.com/articles/s41598-022-15148-z](https://www.nature.com/articles/s41598-022-15148-z)
    3. **Two doses of SARS-CoV-2 vaccination induce robust immune responses to emerging SARS-CoV-2 variants of concern：**[https://www.nature.com/articles/s41467-021-25167-5](https://www.nature.com/articles/s41467-021-25167-5)
    4. **Modeling of waning immunity after SARS-CoV-2 vaccination and influencing factors：**[https://www.nature.com/articles/s41467-022-29225-4](https://www.nature.com/articles/s41467-022-29225-4)
    5. **Effectiveness of an inactivated Covid-19 vaccine with homologous and heterologous boosters against Omicron in Brazil:** [https://www.nature.com/articles/s41467-022-33169-0](https://www.nature.com/articles/s41467-022-33169-0)
    6. **Protection of COVID-19 vaccination and previous infection against Omicron BA.1, BA.2 and Delta SARS-CoV-2 infections:** [https://www.nature.com/articles/s41467-022-31838-8](https://www.nature.com/articles/s41467-022-31838-8)
    7. **Effectiveness and protection duration of Covid-19 vaccines and previous infection against any SARS-CoV-2 infection in young adults:** [https://www.nature.com/articles/s41467-022-31469-z](https://www.nature.com/articles/s41467-022-31469-z)
    8. **Challenges and developments in universal vaccine design against SARS-CoV-2 variants：**[https://www.nature.com/articles/s41541-022-00597-4](https://www.nature.com/articles/s41541-022-00597-4)
    9. **Immunogenicity and efficacy of fourth BNT162b2 and mRNA1273 COVID-19 vaccine doses; three months follow-up：**[https://www.nature.com/articles/s41467-022-35480-2](https://www.nature.com/articles/s41467-022-35480-2)
- 免疫逃逸和再感染
    1. **Characterization of SARS-CoV-2 Spike mutations important for infection of mice and escape from human immune sera：**[https://www.nature.com/articles/s41467-022-30763-0](https://www.nature.com/articles/s41467-022-30763-0)
    2. **SARS-CoV-2 Omicron is an immune escape variant with an altered cell entry pathway：**[https://www.nature.com/articles/s41564-022-01143-7](https://www.nature.com/articles/s41564-022-01143-7)
    3. **Correlation of SARS-CoV-2-breakthrough infections to time-from-vaccine：**[https://www.nature.com/articles/s41467-021-26672-3](https://www.nature.com/articles/s41467-021-26672-3)
    4. **SARS-CoV-2 Delta and Omicron variants evade population antibody response by mutations in a single spike epitope：**[https://www.nature.com/articles/s41564-022-01235-4](https://www.nature.com/articles/s41564-022-01235-4)
    5. **Using multiple sampling strategies to estimate SARS-CoV-2 epidemiological parameters from genomic sequencing data：**[https://www.nature.com/articles/s41467-022-32812-0](https://www.nature.com/articles/s41467-022-32812-0)
    6. **Comparing hybrid and regular COVID-19 vaccine-induced immunity against the Omicron epidemic：**[https://www.nature.com/articles/s41541-022-00594-7](https://www.nature.com/articles/s41541-022-00594-7)
    7. **Risk of SARS-CoV-2 reinfection: a systematic review and meta-analysis：**[https://www.nature.com/articles/s41598-022-24220-7](https://www.nature.com/articles/s41598-022-24220-7)
    8. **Acute and postacute sequelae associated with SARS-CoV-2 reinfection：**[https://www.nature.com/articles/s41591-022-02051-3](https://www.nature.com/articles/s41591-022-02051-3)
- 变异株竞争
    1. **Dynamics of competing SARS-CoV-2 variants during the Omicron epidemic in England：**[https://www.nature.com/articles/s41467-022-32096-4](https://www.nature.com/articles/s41467-022-32096-4)
    2. 
- 人传动物/动物传人
    1. **Transmission of SARS-CoV-2 from humans to animals and potential host adaptation：**[https://www.nature.com/articles/s41467-022-30698-6](https://www.nature.com/articles/s41467-022-30698-6)
    2. **SARS-CoV-2 is transmitted via contact and via the air between ferrets：**[https://www.nature.com/articles/s41467-020-17367-2](https://www.nature.com/articles/s41467-020-17367-2)
- 病毒监测
    1. **Wastewater is a robust proxy for monitoring circulating SARS-CoV-2 variants：**[https://www.nature.com/articles/s41587-022-01388-x](https://www.nature.com/articles/s41587-022-01388-x)
    2. **A novel method to monitor COVID-19 fatality rate in real-time, a key metric to guide public health policy:** [https://www.nature.com/articles/s41598-022-23138-4](https://www.nature.com/articles/s41598-022-23138-4)
- 后遗症
    1. **Long COVID after breakthrough SARS-CoV-2 infection：**[https://www.nature.com/articles/s41591-022-01840-0](https://www.nature.com/articles/s41591-022-01840-0)
- 接种疫苗的影响
    1. **Effect of vaccination on household transmission of SARS-CoV-2 Delta variant of concern：**[https://www.nature.com/articles/s41467-022-31494-y](https://www.nature.com/articles/s41467-022-31494-y)
    2. **etrospectively modeling the effects of increased global vaccine sharing on the COVID-19 pandemic:** [https://www.nature.com/articles/s41591-022-02064-y](https://www.nature.com/articles/s41591-022-02064-y)
    3. **Trends in COVID-19 hospital outcomes in England before and after vaccine introduction, a cohort study:** [https://www.nature.com/articles/s41467-022-32458-y](https://www.nature.com/articles/s41467-022-32458-y)
    4. **The indirect effect of mRNA-based COVID-19 vaccination on healthcare workers’ unvaccinated household members:** [https://www.nature.com/articles/s41467-022-28825-4](https://www.nature.com/articles/s41467-022-28825-4)
    5. **Spatial modeling of vaccine deserts as barriers to controlling SARS-CoV-2：**[https://www.nature.com/articles/s43856-022-00183-8](https://www.nature.com/articles/s43856-022-00183-8)
- 共同感染
    1. **Co-infection with SARS-CoV-2 Omicron and Delta variants revealed by genomic surveillance：**[https://www.nature.com/articles/s41467-022-30518-x](https://www.nature.com/articles/s41467-022-30518-x)
- 超额死亡率+建模
    1. **A framework for reconstructing SARS-CoV-2 transmission dynamics using excess mortality data：**[https://www.nature.com/articles/s41467-022-30711-y](https://www.nature.com/articles/s41467-022-30711-y)
    2. **Global estimates of excess deaths from COVID-19：**[https://www.nature.com/articles/d41586-022-04138-w](https://www.nature.com/articles/d41586-022-04138-w)
- 病死率
    1. **Evolution of the lethality due to SARS-CoV-2 in Spain according to age group and sex：**[https://www.nature.com/articles/s41598-022-25635-y](https://www.nature.com/articles/s41598-022-25635-y)
- 基于网络流行病建模（仿真）
    1. **Using high-resolution contact networks to evaluate SARS-CoV-2 transmission and control in large-scale multi-day events：**[https://www.nature.com/articles/s41467-022-29522-y](https://www.nature.com/articles/s41467-022-29522-y)
    2. **A high-resolution flux-matrix model describes the spread of diseases in a spatial network and the effect of mitigation strategies：**[https://www.nature.com/articles/s41598-022-19931-w](https://www.nature.com/articles/s41598-022-19931-w)
    3. **Spatial epidemiology of networked metapopulation: an overview:** [https://link.springer.com/article/10.1007/s11434-014-0499-8](https://link.springer.com/article/10.1007/s11434-014-0499-8)
    4.   **Modelling the propagation of infectious disease via transportation networks：**[https://www.nature.com/articles/s41598-022-24866-3](https://www.nature.com/articles/s41598-022-24866-3)
- 考虑变异的流行病建模（宏观仿真）
    1. **Modelling the impact of Omicron and emerging variants on SARS-CoV-2 transmission and public health burden：**[https://www.nature.com/articles/s43856-022-00154-z](https://www.nature.com/articles/s43856-022-00154-z)
    2. **Modeling COVID-19 transmission between age groups in the United States considering virus mutations, vaccinations, and reinfection：**[https://www.nature.com/articles/s41598-022-21559-9](https://www.nature.com/articles/s41598-022-21559-9)
    3. **A COVID-19 model incorporating variants, vaccination, waning immunity, and population behavior：**[https://www.nature.com/articles/s41598-022-24967-z](https://www.nature.com/articles/s41598-022-24967-z)
    4. **Bayesian SIR model with change points with application to the Omicron wave in Singapore：**[https://www.nature.com/articles/s41598-022-25473-y](https://www.nature.com/articles/s41598-022-25473-y)
- 仿真框架
    1. **Multi-agent simulation model updating and forecasting for the evaluation of COVID-19 transmission：**[https://www.nature.com/articles/s41598-022-22945-z](https://www.nature.com/articles/s41598-022-22945-z)
- 变异特性
    1. **Genetic variations that increase infectivity of SARS-CoV-2：**[https://www.nature.com/articles/d44151-022-00017-5](https://www.nature.com/articles/d44151-022-00017-5)
    2. **Context-specific emergence and growth of the SARS-CoV-2 Delta variant:** [https://www.nature.com/articles/s41586-022-05200-3](https://www.nature.com/articles/s41586-022-05200-3)
- 估计可再生系数
    1. **Improving local prevalence estimates of SARS-CoV-2 infections using a causal debiasing framework：**[https://www.nature.com/articles/s41564-021-01029-0](https://www.nature.com/articles/s41564-021-01029-0)
- 人类预期寿命
    1. **Quantifying impacts of the COVID-19 pandemic through life-expectancy losses: a population-level study of 29 countries：**[https://academic.oup.com/ije/article/51/1/63/6375510?login=false](https://academic.oup.com/ije/article/51/1/63/6375510?login=false)
    2. **Reduction in life expectancy in Brazil after COVID-19：**[https://www.nature.com/articles/s41591-021-01437-z](https://www.nature.com/articles/s41591-021-01437-z)
    3. **Assessing the potential impact of COVID-19 on life expectancy：**[https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0238678](https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0238678)
    4. **Impact of the COVID-19 pandemic on life expectancy in Madrid (Spain)：**[https://academic.oup.com/jpubhealth/article/42/3/635/5857763?login=false](https://academic.oup.com/jpubhealth/article/42/3/635/5857763?login=false)
    5. **Effects of covid-19 pandemic on life expectancy and premature mortality in 2020: time series analysis in 37 countries：**[https://www.bmj.com/content/375/bmj-2021-066768.short](https://www.bmj.com/content/375/bmj-2021-066768.short)
    6. **The Long-Term Impact of the COVID-19 Unemployment Shock on Life Expectancy and Mortality Rates：**[https://www.nber.org/papers/w28304](https://www.nber.org/papers/w28304)
    7. **Life expectancy changes since COVID-19:** [https://www.nature.com/articles/s41562-022-01450-3](https://www.nature.com/articles/s41562-022-01450-3)
- 直接/间接影响
    1. **Indirect COVID-19 health effects and potential mitigating interventions: Cost-effectiveness framework：**[https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0271523](https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0271523)
    2. **The effect of COVID-19 on the economy: Evidence from an early adopter of localized lockdowns：**[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7897430/](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7897430/)
- 大流行前后影响
    1. **Symptoms of depression and anxiety increased marginally from before to during the COVID-19 pandemic among young adults in Canada：**[https://www.nature.com/articles/s41598-022-20379-1](https://www.nature.com/articles/s41598-022-20379-1)
    2. **Trends in non-COVID-19 hospitalizations prior to and during the COVID-19 pandemic period, United States, 2017–2021:** [https://www.nature.com/articles/s41467-022-33686-y](https://www.nature.com/articles/s41467-022-33686-y)
    3. **Evaluating the potential of suburban and rural areas for tourism and recreation, including individual short-term tourism under pandemic conditions：**[https://www.nature.com/articles/s41598-022-24503-z#Sec29](https://www.nature.com/articles/s41598-022-24503-z#Sec29)
    4. **Impacts of the COVID-19 pandemic on scientists’ productivity in science, technology, engineering, mathematics (STEM), and medicine fields：**[https://www.nature.com/articles/s41599-022-01466-0](https://www.nature.com/articles/s41599-022-01466-0)
    5. **The effect of the COVID-19 pandemic on deceased and living organ donors in the United States of America：**[https://www.nature.com/articles/s41598-022-24351-x](https://www.nature.com/articles/s41598-022-24351-x)
- 影响控制或者传播
    1. **National identity predicts public health support during a global pandemic:** [https://www.nature.com/articles/s41467-021-27668-9](https://www.nature.com/articles/s41467-021-27668-9)
    2. **Investigating healthcare worker mobility and patient contacts within a UK hospital during the COVID-19 pandemic：**[https://www.nature.com/articles/s43856-022-00229-x](https://www.nature.com/articles/s43856-022-00229-x)
- 数据真实性、噪声和缺失
    1. **Quantifying the information in noisy epidemic curves：**[https://www.nature.com/articles/s43588-022-00313-1](https://www.nature.com/articles/s43588-022-00313-1)
    2. **Getting the most out of noisy surveillance data：**[https://www.nature.com/articles/s43588-022-00319-9](https://www.nature.com/articles/s43588-022-00319-9)
    3. **Missing data mean we’ll probably never know how many people died of COVID：**[https://www.nature.com/articles/d41586-022-04422-9](https://www.nature.com/articles/d41586-022-04422-9)
    4. **Eight rules to combat medical misinformation：**[https://www.nature.com/articles/s41591-022-02118-1](https://www.nature.com/articles/s41591-022-02118-1)
- 预测趋势（疫情、医疗资源）
    1. **Short-term local predictions of COVID-19 in the United Kingdom using dynamic supervised machine learning algorithms：**[https://www.nature.com/articles/s43856-022-00184-7](https://www.nature.com/articles/s43856-022-00184-7)
    2. **Forecasting admissions in psychiatric hospitals before and during Covid-19: a retrospective study with routine data：**[https://www.nature.com/articles/s41598-022-20190-y](https://www.nature.com/articles/s41598-022-20190-y)
    3. **Distributed lag inspired machine learning for predicting vaccine-induced changes in COVID-19 hospitalization and intensive care unit admission：**[https://www.nature.com/articles/s41598-022-21969-9](https://www.nature.com/articles/s41598-022-21969-9)
    4. **Short-term local predictions of COVID-19 in the United Kingdom using dynamic supervised machine learning algorithms：**[https://www.nature.com/articles/s43856-022-00184-7](https://www.nature.com/articles/s43856-022-00184-7)
    5. **Using mechanistic model-based inference to understand and project epidemic dynamics with time-varying contact and vaccination rates：**[https://www.nature.com/articles/s41598-022-25018-3](https://www.nature.com/articles/s41598-022-25018-3)
    6. **Development of forecast models for COVID-19 hospital admissions using anonymized and aggregated mobile network data：**[https://www.nature.com/articles/s41598-022-22350-6](https://www.nature.com/articles/s41598-022-22350-6)
    7. **Supporting COVID-19 policy-making with a predictive epidemiological multi-model warning system：**[https://www.nature.com/articles/s43856-022-00219-z](https://www.nature.com/articles/s43856-022-00219-z)
- 网络策略
- 参数估计
    1. **Recursive state and parameter estimation of COVID-19 circulating variants dynamics：**[https://www.nature.com/articles/s41598-022-18208-6](https://www.nature.com/articles/s41598-022-18208-6)
- 政策评估
    1. **Micro-level social structures and the success of COVID-19 national policies：**[https://www.nature.com/articles/s43588-022-00314-0](https://www.nature.com/articles/s43588-022-00314-0)
    2. **Micro-level social structures and the success of COVID-19 national policies:** [https://www.nature.com/articles/s43588-022-00314-0](https://www.nature.com/articles/s43588-022-00314-0)
    3. **Interrupted-time-series analysis of the immediate impact of COVID-19 mitigation measures on preterm birth in China:** [https://www.nature.com/articles/s41467-022-32814-y](https://www.nature.com/articles/s41467-022-32814-y)
- 政策制定
    1. **Empirical evidence on the efficiency of backward contact tracing in COVID-19:** [https://www.nature.com/articles/s41467-022-32531-6](https://www.nature.com/articles/s41467-022-32531-6)
    2. **Efficient and targeted COVID-19 border testing via reinforcement learning:** [https://www.nature.com/articles/s41586-021-04014-z](https://www.nature.com/articles/s41586-021-04014-z)
    3. **Social vulnerability amplifies the disparate impact of mobility on COVID-19 transmissibility across the United States：**[https://www.nature.com/articles/s41599-022-01437-5](https://www.nature.com/articles/s41599-022-01437-5)
    4. **Use of temporal contact graphs to understand the evolution of COVID-19 through contact tracing data：**[https://www.nature.com/articles/s42005-022-01045-4](https://www.nature.com/articles/s42005-022-01045-4)
- 病人监测
    1. **Transition matrices model as a way to better understand and predict intra-hospital pathways of covid-19 patients:** [https://www.nature.com/articles/s41598-022-22227-8](https://www.nature.com/articles/s41598-022-22227-8)
    2. **The effect of COVID-19 on the home behaviours of people affected by dementia:** [https://www.nature.com/articles/s41746-022-00697-4](https://www.nature.com/articles/s41746-022-00697-4)
- 不同波疫情分析
    1. **Characterizing COVID-19 waves in urban and rural districts of India:** [https://www.nature.com/articles/s42949-022-00071-z](https://www.nature.com/articles/s42949-022-00071-z)
- 政策影响
    1. **Quantifying the effect of inequitable global vaccine coverage on the COVID-19 pandemic：**[https://www.nature.com/articles/s41591-022-02065-x](https://www.nature.com/articles/s41591-022-02065-x)
    2. **Covid-19 vaccination programme effectiveness against SARS-CoV-2 related infections, hospital admissions and deaths in the Apulia region of Italy: a one-year retrospective cohort study：**[https://www.nature.com/articles/s41598-022-23235-4](https://www.nature.com/articles/s41598-022-23235-4)
- 机器学习诊断症状
    1. **Faecal microbiome-based machine learning for multi-class disease diagnosis：**[https://www.nature.com/articles/s41467-022-34405-3](https://www.nature.com/articles/s41467-022-34405-3)
    2. **Developing and validating a machine learning prognostic model for alerting to imminent deterioration of hospitalized patients with COVID-19：**[https://www.nature.com/articles/s41598-022-23553-7](https://www.nature.com/articles/s41598-022-23553-7)
- 机器学习+基因序列
    1. **Rapidly identifying new coronavirus mutations of potential concern in the Omicron variant using an unsupervised learning strategy：**[https://www.nature.com/articles/s41598-022-23342-2](https://www.nature.com/articles/s41598-022-23342-2)
    2. **Predicting unseen antibodies’ neutralizability via adaptive graph neural networks：**[https://www.nature.com/articles/s42256-022-00553-w](https://www.nature.com/articles/s42256-022-00553-w)
    3. **An explainable model of host genetic interactions linked to COVID-19 severity：**[https://www.nature.com/articles/s42003-022-04073-6](https://www.nature.com/articles/s42003-022-04073-6)
    4. **The potential of genomics for infectious disease forecasting：**[https://www.nature.com/articles/s41564-022-01233-6](https://www.nature.com/articles/s41564-022-01233-6)
    5. **Deep learning models for predicting RNA degradation via dual crowdsourcing：**[https://www.nature.com/articles/s42256-022-00571-8](https://www.nature.com/articles/s42256-022-00571-8)
- 新冠诊断方法
    1. **Applying fuzzy qualitative comparative analysis to identify typical symptoms of COVID-19 infection in a primary care unit, Rio de Janeiro, Brazil：**[https://www.nature.com/articles/s41598-022-26283-y](https://www.nature.com/articles/s41598-022-26283-y)
    2. **Monocyte distribution width as a pragmatic screen for SARS-CoV-2 or influenza infection：**[https://www.nature.com/articles/s41598-022-24978-w](https://www.nature.com/articles/s41598-022-24978-w)
- 后遗症
    1. **COVID-19 pandemic and hypertension: an updated report from the Japanese Society of Hypertension project team on COVID-19：**[https://www.nature.com/articles/s41440-022-01134-5](https://www.nature.com/articles/s41440-022-01134-5)
    2. **Potential POTS association with COVID-19 vaccination weaker than with COVID-19 infection：**[https://www.nature.com/articles/s44161-022-00194-7](https://www.nature.com/articles/s44161-022-00194-7)
    3. **The risks of POTS after COVID-19 vaccination and SARS-CoV-2 infection: it’s worth a shot：**[https://www.nature.com/articles/s44161-022-00180-z](https://www.nature.com/articles/s44161-022-00180-z)
    4. **Association of COVID-19 with diabetes: a systematic review and meta-analysis：**[https://www.nature.com/articles/s41598-022-24185-7](https://www.nature.com/articles/s41598-022-24185-7)
- 组合病

# 数据

- 病例数据
    1. **Johns Hopkins Coronavirus Resource Center：**[https://coronavirus.jhu.edu/map.html](https://coronavirus.jhu.edu/map.html)
    2. **Our World in Data：**[https://ourworldindata.org/coronavirus](https://ourworldindata.org/coronavirus)
    3. **Worldometer：**[https://www.worldometers.info/coronavirus/](https://www.worldometers.info/coronavirus/)
- 人口流动
    1. **COVID-19 Mobility Data Network:** [https://visualization.covid19mobility.org/?date=2021-09-24&dates=2021-06-24_2021-09-24&region=WORLD](https://visualization.covid19mobility.org/?date=2021-09-24&dates=2021-06-24_2021-09-24&region=WORLD)
- 人类社区活动
    1. **Community Mobility Reports：**[https://www.google.com/covid19/mobility/](https://www.google.com/covid19/mobility/)
- 人类位置信息
    1. **Individuals’ willingness to provide geospatial global positioning system (GPS) data from their smartphone during the COVID-19 pandemic：**[https://www.nature.com/articles/s41599-022-01338-7](https://www.nature.com/articles/s41599-022-01338-7)
- 病例监测数据（区分毒株）
    1. **非洲数据：**[https://www.nature.com/articles/s41564-022-01276-9](https://www.nature.com/articles/s41564-022-01276-9)
    2. **英国数据：**[https://covid19.sanger.ac.uk/lineages/raw?](https://covid19.sanger.ac.uk/lineages/raw?latitude=54.300066&longitude=-0.655225&zoom=5.909629)
- 临床数据
    1. **Statistical biases due to anonymization evaluated in an open clinical dataset from COVID-19 patients：**[https://www.nature.com/articles/s41597-022-01669-9](https://www.nature.com/articles/s41597-022-01669-9)
- 人类接种态度
    1. **Public opinion towards global distribution of COVID-19 vaccines - Data from Germany and the United States：**[https://www.nature.com/articles/s41597-022-01700-z](https://www.nature.com/articles/s41597-022-01700-z)